Want to see FR:ALIKO full AI Analyst Report?
ALIKO Stock Chart & Stats
€1.50
€0.00(0.00%)
At close: 4:00 PM EDT
€1.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.36 - €1.84
Previous CloseN/A
Volume3.01K
Average Volume (3M)3.92K
Market Cap
€23.05M
Enterprise Value€26.87M
Total Cash (Recent Filing)€25.08K
Total Debt (Recent Filing)€4.13M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Oct 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding15,843,148
10 Day Avg. Volume6,627
30 Day Avg. Volume3,924
Financial Highlights & Ratios
PEG Ratio-1.55
Price to Book (P/B)1.16
Price to Sales (P/S)16.02
P/FCF Ratio-19.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€6.90M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp revenue acceleration indicates improving customer adoption and commercial traction. Sustained growth could expand the installed base and increase future consumables and service revenue, supporting a more scalable recurring-revenue model.
Solid Gross MarginA gross margin near 65% suggests the platform, reagent, and diagnostic workflow economics can support attractive contribution margins. If revenue growth continues, this gross-profit base may provide operating leverage once spending becomes more disciplined.
Improving Balance Sheet LeverageLower leverage and substantial equity relative to debt reduce immediate solvency pressure and provide greater financial flexibility. This gives the company more time to commercialize its products and pursue growth without excessive debt burdens.
Bears Say
Large Persistent LossesRevenue growth has not yet translated into operating leverage. Very large, widening losses indicate that fixed costs, development spending, or commercialization expenses remain disproportionate to sales, limiting the credibility of near-term profitability.
Ongoing Cash BurnPersistent negative operating and free cash flow means the business does not currently fund its own operations. Continued investment and commercialization therefore remain dependent on external financing, which can constrain execution and dilute shareholders.
Negative Return On EquityNegative return on equity shows that the sizable equity base is not currently generating profits. If losses continue, retained deficits could gradually erode capital and reduce the balance-sheet cushion that currently offsets the low debt burden.
Ikonisys SA News
ALIKO FAQ
What was Ikonisys SA’s price range in the past 12 months?
Ikonisys SA lowest stock price was €1.36 and its highest was €1.84 in the past 12 months.
What is Ikonisys SA’s market cap?
Ikonisys SA’s market cap is €23.05M.
When is Ikonisys SA’s upcoming earnings report date?
Ikonisys SA’s upcoming earnings report date is Oct 23, 2026 which is in 64 days.
How were Ikonisys SA’s earnings last quarter?
Ikonisys SA released its earnings results on Oct 24, 2025. The company reported -€0.073 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.073.
Is Ikonisys SA overvalued?
According to Wall Street analysts Ikonisys SA’s price is currently Overvalued.
Does Ikonisys SA pay dividends?
Ikonisys SA does not currently pay dividends.
What is Ikonisys SA’s EPS estimate?
Ikonisys SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ikonisys SA have?
Ikonisys SA has 15,843,148 shares outstanding.
What happened to Ikonisys SA’s price movement after its last earnings report?
Ikonisys SA reported an EPS of -€0.073 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ikonisys SA?
Currently, no hedge funds are holding shares in FR:ALIKO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ikonisys SA
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes the Ikoniscope Robotic Microscope, which automates slide manipulation, scanning, and real-time image acquisition and analysis, thereby minimizing human error during diagnostic testing. The company provides a suite of specialized oncoFISH microscopy applications for cancer detection and characterization, such as oncoFISH bladder for analyzing urine samples, oncoFISH her2 for determining HER2 status in breast tissue biopsies, oncoFISH ALK for identifying rearrangements of the ALK gene, and oncoFISH PTEN for detecting PTEN gene deletions in prostate tissue biopsies. Ikonisys also offers tools for characterizing individual circulating tumor cells (CTCs) and analyzing circulating tumor DNA (ctDNA) to provide comprehensive tumor genotype information. Additionally, their Ikonisoft explorer software suite features dedicated FISH scanning applications: Ikonisoft explorer CS for cell suspensions on slides, and Ikonisoft explorer tissue for examining hybridized tissue sections. Finally, the IkoniWAN Gateway provides a secure, validated remote access solution for their Ikoniscope digital microscopy platforms.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Novacyt
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Median Technologies
―